Yes. The first meningococcal polysaccharide vaccine in the United States was licensed in 1974 and was effective against one of the five major types (monovalent) of meningococcus. The current quadrivalent polysaccharide vaccine (Menomune or MPSV4)) was licensed in 1978.
A new meningococcal polysaccharide conjugate vaccine (Menactra or MCV4) was licensed in January 2005. Both vaccines licensed in the U.S. provide protection against the types—A, C, Y, and W-135
To date, no vaccine protects against subtype B which cause nearly a quarter of the meningococcal disease cases in the United States.
Immunization is recommended for the following groups: